The Antibody Engineering Unit allows Weizmann’s scientists access to advanced protocols to preserve, generate and modify in-house antibodies.
Current Services
-
Antibody production
In the antibody laboratory we develop monoclonal antibodies against different antigens which are provided by the customer either using hybridoma or single cell sequencing approaches.
-
Hybridoma Sequencing
Hybridomas secreting highly validated antibodies, take a significant time and resources to develop but are easily lost due to contamination, naturally occurring isotype switching or antibody production diminishes over time. Therefore, it is crucial to preserve valuable Antibody sequences following monoclonal antibody production or immediately upon receiving an outsourced Antibody producing hybridoma.
-
Hybridoma screening – to verify single clone origin
Production of a monoclonal antibody is often the key to its function, and any heterogeneity may influence our ability to establish the efficiency of the antibody. Therefore, it is important to verify monoclonality of each in-house or outsourced antibody producing hybridoma.
-
Switching Antibody Subtypes
In the unit, we can switch antibody subtypes from IgG2a/b/IgG3 to IgG1 and vise versa
-
Switch Antibody Species
In the unit, we can switch antibody species from murine to human (producing a chimeric antibody)
-
Switch Antibody Isotypes
In the unit, we can switch antibody isotypes from IgM to IgG
-
Reformat the Antibody
We offer to humanize the chimeric antibody via alignment with human germline sequences using improved Antibody-Antigen affinity using principles for computational design of binding.
-
Large scale Antibody production
We use an adapted Bioreactor system to produce large antibody quantities from hybridoma cell lines.
-
Antibody engineering into different formats
We offer to engineer existing monoclonal antibodies into different formats: e.g. Antibodies fused to proteins, bispecific antibodies, Antibody- fragments (ScFv, nanobodies) etc.